Standout Papers

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study 2016 2026 2019 2022 332
  1. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study (2016)
    Céline Berthon, Emmanuel Raffoux et al. The Lancet Haematology

Immediate Impact

6 by Nobel laureates 31 from Science/Nature 95 standout
Sub-graph 1 of 18

Citing Papers

Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
2023 Standout
The central role of DNA damage in the ageing process
2021 StandoutNature
1 intermediate paper

Works of David Taussig being referenced

Improving CRISPR–Cas specificity with chemical modifications in single-guide RNAs
2017
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
2005

Author Peers

Author Last Decade Papers Cites
David Taussig 1642 1560 756 934 54 3.1k
Faiyaz Notta 1318 1814 1078 1070 50 3.8k
Kristin J. Hope 1166 1590 569 1077 37 2.9k
Claudia S. Huettner 1489 1513 929 710 44 3.2k
Peter van Galen 1149 2363 666 1066 41 3.7k
Hirokazu Shigematsu 1379 2333 1557 812 33 4.2k
Olga I. Gan 1574 2003 1134 1029 51 4.1k
Sergei Doulatov 1430 2079 1014 538 53 3.7k
Monica Doedens 1676 1313 954 823 28 3.2k
Owen N. Witte 555 1200 736 925 46 3.0k
Thomas Look 995 2095 324 873 36 3.1k

All Works

Loading papers...

Rankless by CCL
2026